{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:58:20Z","timestamp":1785355100716,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Open Project of Henan Clinical Research Center of Infectious Diseases","award":["No.KFKT202411"],"award-info":[{"award-number":["No.KFKT202411"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:p>\n                    Although direct-acting antiviral agents (DAAs) have significantly increased the cure rate of hepatitis C, the risk factors for virological recurrence and dynamic changes in liver and kidney functions after treatment in the real world still need to be further clarified. A total of 196 patients with hepatitis C virus (HCV) infection admitted to Henan Infectious Disease Hospital from January 2022 to July 2025 were retrospectively included. Baseline data and laboratory indicators at 12 weeks after the end of DAA treatment, sustained virological response (SVR) rate at 12 and 24 weeks after the end of treatment were collected. Changes in liver function, noninvasive liver fibrosis score and safety indicators before and after treatment were compared. The binary logistic regression model was used to analyze the influencing factors of recurrence in patients with HCV. The virological recurrence rate after DAA treatment was 5.10% (10\/196), and platelet count, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, \u03b1-fetoprotein, and aminotransferase to platelet ratio index decreased significantly after treatment (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). All 10 relapsed patients achieved SVR12, while 4 did not reach SVR24. The time interval from achieving SVR12 to relapse ranged from 5 to 63 weeks. The results of logistic multivariate analysis showed that a previous history of hepatitis C treatment and concurrent HIV infection were risk factors for hepatitis C recurrence in patients. In this real-world cohort, DAA therapy achieved high 12-week efficacy (SVR12 100%), but 5.10% of patients experienced virological relapse within 63 weeks. Achievement of SVR12 was accompanied by significant improvements in liver function and noninvasive fibrosis scores. Prior HCV treatment experience and HIV coinfection were independent predictors of relapse, underscoring the need for prolonged RNA monitoring in these subgroups.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045823","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:00:28Z","timestamp":1762538428000},"page":"e45823","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for virological relapse and long-term efficacy of direct-acting antiviral agents in chronic hepatitis C infection: Impact of HIV coinfection and renal function changes"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0907-2225","authenticated-orcid":false,"given":"Meng","family":"Deng","sequence":"first","affiliation":[{"name":"Clinical Research Center, Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China"},{"name":"Office of Clinical Medical Research Center for Infectious Diseases (AIDS), Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China"},{"name":"Office of Clinical Medical Research Center for Infectious Diseases (AIDS), Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China"},{"name":"Office of Clinical Medical Research Center for Infectious Diseases (AIDS), Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyun","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China"},{"name":"Office of Clinical Medical Research Center for Infectious Diseases (AIDS), Henan Provincial Hospital of Infectious Diseases, Zhengzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260729","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ijc.33313","article-title":"Is it possible to halve the incidence of liver cancer in China by 2050?","volume":"148","author":"Shi","year":"2021","journal-title":"Int J Cancer"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"e22362","DOI":"10.1097\/MD.0000000000022362","article-title":"Association of cytokine gene polymorphisms with chronic hepatitis C virus genotype 1b infection in Chinese Han population: an observational study.","volume":"99","author":"Jing","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eimc.2019.07.009","article-title":"Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: validation in a real-life cohort of HIV-coinfected patients.","volume":"38","author":"Dom\u00ednguez-Dom\u00ednguez","year":"2020","journal-title":"Enferm Infecc Microbiol Clin (Engl ed)"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jvh.13543","article-title":"Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.","volume":"28","author":"McDonald","year":"2021","journal-title":"J Viral Hepat"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/v11050406","article-title":"Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral agents.","volume":"11","author":"Sanduzzi-Zamparelli","year":"2019","journal-title":"Viruses"},{"key":"R7-20260729","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4254\/wjh.v10.i11.856","article-title":"Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV\/HCV coinfected patients.","volume":"10","author":"Salmon","year":"2018","journal-title":"World J Hepatol"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/LVT.0000000000000603","article-title":"Combining radiomics and imaging biomarkers with clinical variables for the prediction of HCC recurrence after liver transplantation.","volume":"31","author":"Schindler","year":"2025","journal-title":"Liver Transplant"},{"key":"R9-20260729","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3748\/wjg.v27.i21.2771","article-title":"Direct antiviral agents in hepatitis C virus related liver disease: don\u2019t count the chickens before they\u2019re hatched.","volume":"27","author":"Compagnoni","year":"2021","journal-title":"World J Gastroenterol"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"e70007","DOI":"10.1002\/prp2.70007","article-title":"High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: a cohort study conducted in Vietnam.","volume":"12","author":"Vo","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review.","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12072-018-9895-5","article-title":"Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.","volume":"12","author":"Ooka","year":"2018","journal-title":"Hepatol Int"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s10620-022-07629-y","article-title":"Improved liver function after sustained virologic response enhanced prognosis in hepatitis C with compensated advanced liver fibrosis.","volume":"68","author":"Tahata","year":"2023","journal-title":"Dig Dis Sci"},{"key":"R14-20260729","doi-asserted-by":"crossref","first-page":"100994","DOI":"10.1016\/j.jhepr.2023.100994","article-title":"Real-world effectiveness of voxilaprevir\/velpatasvir\/sofosbuvir in patients following DAA failure.","volume":"6","author":"Graf","year":"2024","journal-title":"JHEP Rep"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"27","DOI":"10.34172\/mejdd.2021.200","article-title":"Effect of baseline resistance-associated substitutions on thalassemia patients with chronic HCV infection: a two-year follow-up.","volume":"13","author":"Safarnezhad Tameshkel","year":"2021","journal-title":"Middle East J Digest Dis"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.","volume":"77","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"103981","DOI":"10.1016\/j.drugpo.2023.103981","article-title":"The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.","volume":"114","author":"Young","year":"2023","journal-title":"Int J Drug Policy"},{"key":"R18-20260729","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/j.gastro.2009.06.040","article-title":"Coinfection with HIV-1 and HCV--a one-two punch.","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"key":"R19-20260729","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/jvh.12967","article-title":"Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.","volume":"25","author":"Hayashi","year":"2018","journal-title":"J Viral Hepat"},{"key":"R20-20260729","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis.","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"key":"R21-20260729","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/v15071489","article-title":"Treatment outcomes of sofosbuvir\/velpatasvir\/voxilaprevir in direct-acting antiviral-experienced hepatitis C virus patients: a systematic review and meta-analysis.","volume":"15","author":"Devan","year":"2023","journal-title":"Viruses"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:00:49Z","timestamp":1785351649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":20,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045823","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-07-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}